$STSS
Sharps Technology Inc.

2024 Q4 Form 10-Q Financial Statement

#000149315224045732 Filed on November 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development $145.6K
YoY Change -35.34%
% of Gross Profit
Depreciation & Amortization $194.5K
YoY Change -7.39%
% of Gross Profit
Operating Expenses $2.015M
YoY Change -14.55%
Operating Profit -$2.015M
YoY Change -14.55%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $330.1K
YoY Change -1.75%
Pretax Income
YoY Change
Income Tax
% Of Pretax Income
Net Earnings -$1.685M
YoY Change -16.68%
Net Earnings / Revenue
Basic Earnings Per Share -$1.27
Diluted Earnings Per Share -$1.27
COMMON SHARES
Basic Shares Outstanding 1.798M shares 28.59M shares
Diluted Shares Outstanding 1.332M shares

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $2.473M
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory $2.019M
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $4.654M
YoY Change -32.86%
LONG-TERM ASSETS
Property, Plant & Equipment $6.234M
YoY Change -9.83%
Goodwill
YoY Change
Intangibles $40.23K
YoY Change -23.84%
Long-Term Investments
YoY Change
Other Assets $366.3K
YoY Change -30.46%
Total Long-Term Assets $6.600M
YoY Change -11.29%
TOTAL ASSETS
Total Short-Term Assets $4.654M
Total Long-Term Assets $6.600M
Total Assets $11.25M
YoY Change -21.69%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $945.6K
YoY Change 5.07%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.586M
YoY Change 27.96%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $4.586M
Total Long-Term Liabilities
Total Liabilities $4.748M
YoY Change 25.74%
SHAREHOLDERS EQUITY
Retained Earnings -$29.92M
YoY Change 35.7%
Common Stock $170.00
YoY Change -88.87%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $6.506M
YoY Change
Total Liabilities & Shareholders Equity $11.25M
YoY Change -21.69%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$1.685M
YoY Change -16.68%
Depreciation, Depletion And Amortization $194.5K
YoY Change -7.39%
Cash From Operating Activities -$1.643M
YoY Change -18.24%
INVESTING ACTIVITIES
Capital Expenditures $50.30K
YoY Change -145.73%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change -100.0%
Cash From Investing Activities -$50.30K
YoY Change -44.11%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.736M
YoY Change -42.89%
NET CHANGE
Cash From Operating Activities -1.643M
Cash From Investing Activities -50.30K
Cash From Financing Activities 2.736M
Net Change In Cash 1.042M
YoY Change -61.27%
FREE CASH FLOW
Cash From Operating Activities -$1.643M
Capital Expenditures $50.30K
Free Cash Flow -$1.694M
YoY Change -10.85%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
usd
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-41355
dei Entity Registrant Name
EntityRegistrantName
Sharps Technology, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-3751728
dei Entity Address Address Line1
EntityAddressAddressLine1
105 Maxess Road
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2358358 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-5780362 usd
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001737995
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Entity Address City Or Town
EntityAddressCityOrTown
Melville
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
11747
dei City Area Code
CityAreaCode
(631)
dei Local Phone Number
LocalPhoneNumber
574 -4436
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2473197 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
161337 usd
CY2024Q3 us-gaap Inventory Net
InventoryNet
2019481 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
4654015 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6233595 usd
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
366288 usd
CY2024Q3 us-gaap Assets
Assets
11253898 usd
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
945625 usd
CY2024Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
279326 usd
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
dei Entity Listing Par Value Per Share
EntityListingParValuePerShare
0.0001
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3012908 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
116508 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
1709135 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
4838551 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6822142 usd
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
128575 usd
CY2023Q4 us-gaap Assets
Assets
11789268 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
794107 usd
CY2023Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
476090 usd
dei Amendment Flag
AmendmentFlag
false
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
usd
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
usd
CY2024Q3 us-gaap Stock Redeemed Or Called During Period Value
StockRedeemedOrCalledDuringPeriodValue
usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
usd
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
usd
STSS Escrow Deposit Forfeited
EscrowDepositForfeited
usd
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
usd
CY2024Q3 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
usd
CY2023Q3 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
usd
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
usd
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
usd
STSS Share Based Compensation Arrangement By Share Based Payment Award Options Granted In Year
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInYear
P5Y
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
1797795 shares
CY2024Q3 us-gaap Notes Payable Current
NotesPayableCurrent
2334142 usd
CY2024Q3 STSS Warrant Liabilities Current
WarrantLiabilitiesCurrent
1027102 usd
CY2023Q4 STSS Warrant Liabilities Current
WarrantLiabilitiesCurrent
2422785 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
4586195 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3692982 usd
CY2024Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
162000 usd
CY2023Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
162000 usd
CY2024Q3 us-gaap Liabilities
Liabilities
4748195 usd
CY2023Q4 us-gaap Liabilities
Liabilities
3854982 usd
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
1 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
1 shares
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1694110 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1694110 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
694294 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
694294 shares
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
170 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
69 usd
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
35941738 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
32491409 usd
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
482572 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
591812 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-29918777 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-25149004 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
6505703 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
7934286 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
11253898 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
11789268 usd
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
145611 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
225191 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
523347 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
783340 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1869598 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2133167 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5257015 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6425154 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
2015209 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
2358358 usd
us-gaap Operating Expenses
OperatingExpenses
5780362 usd
us-gaap Operating Expenses
OperatingExpenses
7208494 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2015209 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-7208494 usd
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-70905 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
17620 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1046593 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
94492 usd
CY2024Q3 us-gaap Gain Loss On Sale Of Derivatives
GainLossOnSaleOfDerivatives
416560 usd
CY2023Q3 us-gaap Gain Loss On Sale Of Derivatives
GainLossOnSaleOfDerivatives
321981 usd
us-gaap Gain Loss On Sale Of Derivatives
GainLossOnSaleOfDerivatives
2088747 usd
us-gaap Gain Loss On Sale Of Derivatives
GainLossOnSaleOfDerivatives
415958 usd
CY2024Q3 STSS Foreign Currency And Non Operating Income Expenses
ForeignCurrencyAndNonOperatingIncomeExpenses
-15506 usd
CY2023Q3 STSS Foreign Currency And Non Operating Income Expenses
ForeignCurrencyAndNonOperatingIncomeExpenses
-3587 usd
STSS Foreign Currency And Non Operating Income Expenses
ForeignCurrencyAndNonOperatingIncomeExpenses
-31566 usd
STSS Foreign Currency And Non Operating Income Expenses
ForeignCurrencyAndNonOperatingIncomeExpenses
-41955 usd
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
330149 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
336014 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1010588 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
468495 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-1685060 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-2022344 usd
us-gaap Net Income Loss
NetIncomeLoss
-4769774 usd
us-gaap Net Income Loss
NetIncomeLoss
-6739999 usd
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.27
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.27
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.77
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.77
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.53
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.53
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-13.01
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-13.01
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1331891 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1331891 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
536886 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
536886 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1053259 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1053259 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
518166 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
518166 shares
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-1685060 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-2022344 usd
us-gaap Net Income Loss
NetIncomeLoss
-4769774 usd
us-gaap Net Income Loss
NetIncomeLoss
-6739999 usd
CY2024Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
130723 usd
CY2023Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-283544 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-109241 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
61314 usd
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1554337 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2305888 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4879015 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6678685 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
7934286 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-982386 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
126387 usd
CY2024Q1 STSS Stock Issued During Period Value Exercise Of Prefunded Warrants
StockIssuedDuringPeriodValueExerciseOfPrefundedWarrants
396 usd
CY2024Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
-218053 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
6860630 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-2102327 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
201918 usd
CY2024Q2 STSS Stock Issued During Period Value Exercise Of Prefunded Warrant
StockIssuedDuringPeriodValueExerciseOfPrefundedWarrant
2985 usd
CY2024Q2 STSS Stock Issued During Period Value Registration Offering
StockIssuedDuringPeriodValueRegistrationOffering
1296922 usd
CY2024Q2 STSS Stock Issued During Period Value Warrant Inducements
StockIssuedDuringPeriodValueWarrantInducements
978981 usd
CY2024Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
-21911 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
7217198 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-1685060 usd
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
116193 usd
CY2024Q3 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
726350 usd
CY2024Q3 STSS Stock Issued During Period Value Warrant Exericse
StockIssuedDuringPeriodValueWarrantExericse
298 usd
CY2024Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
130723 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
6505703 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
9641134 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2111830 usd
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2783385 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
383100 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
270983 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
10966772 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-2605825 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
254446 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
73876 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
8689269 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
8689269 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-2022344 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-2022344 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
201365 usd
CY2023Q3 STSS Stock Issued During Period Value Shelf Registration Offering
StockIssuedDuringPeriodValueShelfRegistrationOffering
2458004 usd
CY2023Q3 STSS Stock Issued During Period Value Private Placement
StockIssuedDuringPeriodValuePrivatePlacement
1552819 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
-283544 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
10595569 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
10595569 usd
us-gaap Net Income Loss
NetIncomeLoss
-4769774 usd
us-gaap Net Income Loss
NetIncomeLoss
-6739999 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
583006 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
656100 usd
us-gaap Share Based Compensation
ShareBasedCompensation
444498 usd
us-gaap Share Based Compensation
ShareBasedCompensation
838911 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
75192 usd
us-gaap Gain Loss On Sale Of Derivatives
GainLossOnSaleOfDerivatives
2088747 usd
us-gaap Gain Loss On Sale Of Derivatives
GainLossOnSaleOfDerivatives
415958 usd
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
205112 usd
STSS Escrow Deposit Forfeited
EscrowDepositForfeited
1000000 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-31566 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-33729 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
47233 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
23032 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
349317 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1039152 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-51326 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
339352 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5172135 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6144937 usd
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
69659 usd
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
232295 usd
STSS Escrow Payment Under Agreement
EscrowPaymentUnderAgreement
1000000 usd
STSS Escrow Payment Under Agreement
EscrowPaymentUnderAgreement
199084 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1069659 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-431379 usd
STSS Net Proceeds From Offerings And Warrant Exercises
NetProceedsFromOfferingsAndWarrantExercises
2972646 usd
STSS Net Proceeds From Offerings And Warrant Exercises
NetProceedsFromOfferingsAndWarrantExercises
8029628 usd
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
2735300 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5707946 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8029628 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-5863 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-69792 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-539711 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1383520 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
3012908 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
4170897 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2473197 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
5554417 usd
CY2024Q3 STSS Working Capital
WorkingCapital
67820 usd
CY2024Q4 STSS Reverse Stock Split Description
ReverseStockSplitDescription
the Company completed a 1 for 22 reverse split, whereby for each 22 shares of common stock the Company issued one share of common stock .
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84C_eus-gaap--UseOfEstimates_zGgGkPhMhNe2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Use of Estimates</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. As of September 30, 2024, the most significant estimates relate to derivative liabilities, stock-based compensation, long-lived asset impairments and accounting for debt and equity financing.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0 usd
CY2023Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0 usd
us-gaap Loss Contingency Disclosures
LossContingencyDisclosures
<p id="xdx_843_eus-gaap--LossContingencyDisclosures_zUwxnT86suvh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Contingencies</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liabilities for loss contingencies arising from claims, assessments, litigations, fines and penalties and other sources are recognized when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated. Gain contingencies are evaluated and not recognized until the gain is realizable or realized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
360907 usd
CY2023Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
254461 usd
CY2024Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
140025 usd
CY2023Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
170464 usd
CY2024Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1518549 usd
CY2023Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1284210 usd
CY2024Q3 us-gaap Inventory Net
InventoryNet
2019481 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
1709135 usd
CY2024Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8224960 usd
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8037928 usd
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1991365 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1215786 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6233595 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6822142 usd
us-gaap Depreciation
Depreciation
574719 usd
us-gaap Depreciation
Depreciation
646538 usd
CY2024Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
40227 usd
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
52513 usd
CY2024Q3 us-gaap Other Assets Miscellaneous Noncurrent
OtherAssetsMiscellaneousNoncurrent
326061 usd
CY2023Q4 us-gaap Other Assets Miscellaneous Noncurrent
OtherAssetsMiscellaneousNoncurrent
76062 usd
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
366288 usd
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
128575 usd
STSS Accreted Interest Fees
AccretedInterestFees
75192 usd
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000 shares
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2019Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000 shares
CY2019Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q1 us-gaap Conversion Of Stock Description
ConversionOfStockDescription
Pursuant to the merger agreement, (i) the Company merged with and into Sharps Nevada, (ii) each 3.5 shares of common stock of the Company were converted into one share of common stock of Sharps Nevada and (iii) the articles of incorporation and bylaws of Sharps Nevada, became the articles of incorporation and bylaws of the surviving corporation.
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000 shares
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2022Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2023Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5600000 usd
CY2023Q3 us-gaap Other Expenses
OtherExpenses
716000 usd
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
9000000.0 usd
CY2022Q2 STSS Warrant Liabilities Current
WarrantLiabilitiesCurrent
5200000 usd
CY2024Q3 STSS Warrant Liabilities Current
WarrantLiabilitiesCurrent
1027102 usd
CY2023Q4 STSS Warrant Liabilities Current
WarrantLiabilitiesCurrent
2422785 usd
CY2024Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
804383 shares
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1194495 shares
CY2024Q3 us-gaap Gain Loss On Sale Of Derivatives
GainLossOnSaleOfDerivatives
416560 usd
CY2024Q3 STSS Fair Value Adjustment Of Modification Charge
FairValueAdjustmentOfModificationCharge
155703 usd
us-gaap Gain Loss On Sale Of Derivatives
GainLossOnSaleOfDerivatives
2088747 usd
STSS Fair Value Adjustment Of Modification Charge
FairValueAdjustmentOfModificationCharge
790956 usd
CY2023Q3 STSS Gain Loss On Sale Of Derivative
GainLossOnSaleOfDerivative
-321981 usd
STSS Gain Loss On Sale Of Derivative
GainLossOnSaleOfDerivative
415958 usd
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
109493 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
67.12
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
63409 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.27
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
18592 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
37.11
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
154310 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
42.88
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
122243 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
50.86
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P39M
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
63409 shares
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 STSS Share Based Compensation Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationOptionsExercisableWeightedAverageExercisePrice
6.27
CY2024Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
232353 usd
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
7.25
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P12M
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
116193 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
435908 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2024Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0 pure
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0 pure
CY2023Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0 pure
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0 pure
CY2024Q3 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
2473197 usd
CY2024Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
2473197 usd
CY2024Q3 us-gaap Derivative Liabilities
DerivativeLiabilities
1027102 usd
CY2024Q3 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
1027102 usd
CY2023Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
3012908 usd
CY2023Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
3012908 usd
CY2023Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
2422785 usd
CY2023Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
2422785 usd

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0001493152-24-045732-index-headers.html Edgar Link pending
0001493152-24-045732-index.html Edgar Link pending
0001493152-24-045732.txt Edgar Link pending
0001493152-24-045732-xbrl.zip Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
form10q_htm.xml Edgar Link completed
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
stss-20240930.xsd Edgar Link pending
stss-20240930_cal.xml Edgar Link unprocessable
stss-20240930_def.xml Edgar Link unprocessable
stss-20240930_lab.xml Edgar Link unprocessable
stss-20240930_pre.xml Edgar Link unprocessable